Comprehensive analysis of a novel cuproptosis-related lncRNA signature associated with prognosis and tumor matrix features to predict immunotherapy in soft tissue carcinoma

Abstract

Background: A crucial part of the malignant processes of soft tissue sarcoma (STS) is played by cuproptosis and lncRNAs. However, the connection between cuproptosis-related lncRNAs (CRLs) and STS is nevertheless unclear. As a result, our objective was to look into the immunological activity, clinical significance, and predictive accuracy of CRLs in STS.Methods: The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases, respectively, provided information on the expression patterns of STS patients and the general population. Cuproptosis-related lncRNA signature (CRLncSig) construction involved the univariate, multivariate, and least absolute shrinkage and selection operator Cox regression analysis. The predictive performance of the CRLncSig was evaluated using a serial analysis. Further research was done on the connections between the CRLncSig and the tumor immune milieu, somatic mutation, immunotherapy response, and chemotherapeutic drug susceptibility. Notably, an in vitro investigation served to finally validate the expression of the hallmark CRLs.Results: A novel efficient CRLncSig composed of seven CRLs was successfully constructed. Additionally, the low-CRLncSig group’s prognosis was better than that of the high-CRLncSig group’s based on the new CRLncSig. The innovative CRLncSig then demonstrated outstanding, consistent, and independent prognostic and predictive usefulness for patients with STS, according to the evaluation and validation data. The low-CRLncSig group’s patients also displayed improved immunoreactivity phenotype, increased immune infiltration abundance and checkpoint expression, and superior immunotherapy response, whereas those in the high-CRLncSig group with worse immune status, increased tumor stemness, and higher collagen levels in the extracellular matrix. Additionally, there is a noticeable disparity in the sensitivity of widely used anti-cancer drugs amongst various populations. What’s more, the nomogram constructed based on CRLncSig and clinical characteristics of patients also showed good predictive ability. Importantly, Real-Time Quantitative Polymerase Chain Reaction (RT-qPCR) demonstrated that the signature CRLs exhibited a significantly differential expression level in STS cell lines.Conclusion: In summary, this study revealed the novel CRLncSig could be used as a promising predictor for prognosis prediction, immune activity, tumor immune microenvironment, immune response, and chemotherapeutic drug susceptibility in patients with STS. This may provide an important direction for the clinical decision-making and personalized therapy of STS.

Development of a prognostic Neutrophil Extracellular Traps related lncRNA signature for soft tissue sarcoma using machine learning

“…Research has established the importance of the cancer immune cycle as a framework for guiding cancer immunotherapy. Moreover, the immune atlas radar map demonstrated that immune features such as Cytolytic activity, Inflammation promotion, and APC co-inhibition were predominantly enriched in the low NETsLnc group, consistent with prior evidence ( 5 , 46 ). Collectively, these findings suggest that the NETsLnc group exhibits notable tumor-related and immune characteristics, potentially indicating a relationship with the tumor immune microenvironment and immunotherapy.…”

Novel cuproptosis-related lncRNAs can predict the prognosis of patients with multiple myeloma

“…There is an urgent demand for identifying reliable prognostic biomarkers and new therapeutic targets for MM. In recent years, the contribution of lncRNAs to cancer progression has been widely recognized ( 42 , 43 ). Li ( 44 ) found that cuproptosis played an important role in hematological tumors.…”

Integrative profiling analysis reveals prognostic significance, molecular characteristics, and tumor immunity of angiogenesis-related genes in soft tissue sarcoma

“…The sources of the cell lines used in the present study were all described in previous research ( 25 ). All the cell lines were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Procell) containing 10% fetal bovine serum and 1% penicillin-streptomycin solution.…”